Gregor Diagnostics

gregordiagnostics.com →

+27%

est. 2Y upside i

HealthcareSeries A

Rank

#2067

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Low

Given the pre-revenue clinical stage, missing valuation, and high incumbent threat, the equity upside is highly uncertain.

Last updated: July 3, 2026

Bull (10%)+180%

Acquisition by a major diagnostics player at $100M exit (4.6x on ~$22M entry). Driven by strong IP and large TAM, but low probability given high incumbent threat and CEO departure.

Base (55%)+80%

Moderate exit at $50M (2.3x entry) after FDA approval, with ongoing dilution and competitive pressure from Exact Sciences and Myriad Genetics.

Bear (35%)-100%

Failure to achieve FDA approval or secure funding, resulting in total loss. Preference stack wipes out common stock at exit below $14.6M.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Funding Intensity

6670%

Total funding of $14.6M likely exceeds entry valuation of ~$22M, meaning preferred stock holds a large overhang and common stock could be wiped out in a downside exit.

Dilution Risk

high

With no revenue and capital-intensive operations, the company will likely require additional funding within 2 years, diluting common equity by 15-25%.

Secondary Liquidity

none

No secondary market exists for these shares; liquidity is tied to an exit event, which is likely years away.

Questions to Ask at the Interview

Strategic questions based on Gregor Diagnostics's data — designed to show you've done your homework.

  • 1

    “How do you plan to differentiate from Exact Sciences and other incumbent diagnostics players given your pre-revenue stage?”

  • 2

    “What is your timeline and path to FDA approval, and what milestones are expected in the next 2 years?”

  • 3

    “How has the CEO departure in early 2026 affected team morale and the company's strategic direction?”

Community

Valuation Sentiment

Our model estimates +27% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.